Search Result

Results for "

appetite

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Acyltransferase (2) Adrenergic Receptor (3) Aminotransferases (Transaminases) (1) Amylin Receptor (4) Apoptosis (9) Autophagy (12) Bacterial (1) Bcl-2 Family (8) Biochemical Assay Reagents (2) Bombesin Receptor (1) Calcium Channel (1) Cannabinoid Receptor (6) Cholecystokinin Receptor (1) Cytochrome P450 (1) Drug Derivative (2) Endogenous Metabolite (28) Environmental Pollutants (2) Free Fatty Acid Receptor (1) G protein-coupled Bile Acid Receptor 1 (1) GCGR (3) GHSR (6) GLP Receptor (10) Histone Methyltransferase (1) HIV (4) Insulin Receptor (12) Isotope-Labeled Compounds (12) Melanocortin Receptor (4) MetAP (2) Neurokinin Receptor (1) Neuropeptide FF Receptor (3) Neuropeptide Y Receptor (14) NF-κB (3) Orexin Receptor (OX Receptor) (5) p38 MAPK (8) PERK (1) Progesterone Receptor (4) Reference Standards (12) Serotonin Transporter (3) TGF-β Receptor (1) Tyrosinase (2) α-synuclein (8)
By Research Areas:	Cancer (26) Cardiovascular Disease (5) Endocrinology (13) Infection (3) Inflammation/Immunology (7) Metabolic Disease (70) Neurological Disease (50)
Oligonucleotides:	Sweetening Agents (1)

113

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Y0337

L-Cysteine Maximum Cited Publications 12 Publications Verification Cysteine	Environmental Pollutants Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
L-Cysteine (Cysteine) is an orally active conditionally essential amino acid with hypoglycemic effects, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine promotes the proliferation and differentiation of neural stem cells via the CBS/H2S pathway. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. L-Cysteine can be used as an anorectic agent .

HY-P10798

Eloralintide LY-3841136	Amylin Receptor	Metabolic Disease
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity .

HY-Y0337A

L-Cysteine hydrochloride Maximum Cited Publications 12 Publications Verification	Endogenous Metabolite	Metabolic Disease Cancer
L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) .

HY-N0614

Sucralose 3 Publications Verification E955; Trichlorosucrose	Endogenous Metabolite	Cancer
Sucralose (E955; Trichlorosucrose) is a non-nutritive artificial sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cannabinoid Receptor	Others
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-13676

Megestrol acetate 2 Publications Verification	Progesterone Receptor Autophagy HIV	Endocrinology Cancer
Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-14734

Anamorelin 5+ Cited Publications RC-1291; ONO-7643	GHSR	Endocrinology Cancer
Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC₅₀ of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .

HY-P10746

EB1002	Neurokinin Receptor	Metabolic Disease
EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes .

HY-P10798A

Eloralintide sodium LY-3841136 sodium	Amylin Receptor Calcium Channel	Metabolic Disease
Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca ²⁺ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity .

HY-W016715

L-Cysteine hydrochloride hydrate Maximum Cited Publications 12 Publications Verification	Endogenous Metabolite NF-κB Insulin Receptor	Neurological Disease Metabolic Disease
L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes .

HY-P11274A

Zenagamtide sodium Amycretin sodium; NN 9487 sodium	Amylin Receptor Insulin Receptor GCGR	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-Y0337S5

L-Cysteine-d3	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
L-Cysteine-d₃ is the deuterium labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-18678A

Bremelanotide Acetate 1 Publications Verification PT-141 Acetate	Melanocortin Receptor	Metabolic Disease
Bremelanotide (PT-141) Acetate is a melanocortin receptor agonist. Bremelanotide Acetate can activate MC4R and increases dopamine release. Bremelanotide Acetate induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide Acetate can be used for the research of hypoactive sexual desire disorders .

HY-B1716

L-5-Hydroxytryptophan 3 Publications Verification L-5-HTP; Oxitriptan	Endogenous Metabolite	Neurological Disease Metabolic Disease
L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-Y0079

D-Phenylalanine	Endogenous Metabolite	Infection
D-Phenylalanine is an atypical D-amino acid and an inhibitor of bacterial biofilm formation. D-Phenylalanine mainly replaces D-alanine (D-Ala) by incorporating into the fourth and fifth positions of bacterial peptidoglycan (PG), changing the cell wall structure, enhancing bacterial acid resistance and affecting biofilm formation. D-Phenylalanine may promote the secretion of peptide tyrosine tyrosine (PYY) in mammals by activating the intestinal GPR109B receptor. D-Phenylalanine can inhibit the maturation of microbial biofilms and promote the release of specific hormones. It can be used for antibacterial preservation, improving the yield of probiotics in the food industry, and studying appetite regulation and blood sugar control in metabolic diseases such as diabetes .

HY-14734A

Anamorelin hydrochloride 5+ Cited Publications RC-1291 hydrochloride; ONO-7643 hydrochloride	GHSR	Endocrinology Cancer
Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC₅₀ of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia .

HY-18678

Bremelanotide 1 Publications Verification PT-141	Melanocortin Receptor	Neurological Disease Metabolic Disease
Bremelanotide (PT-141) is a melanocortin receptor agonist. Bremelanotide can activate MC4R and increases dopamine release. Bremelanotide induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide can be used for the research of hypoactive sexual desire disorders .

HY-106224B

Orexin A (human, rat, mouse) acetate 10+ Cited Publications Hypocretin-1 (human, rat, mouse) acetate	Orexin Receptor (OX Receptor)	Neurological Disease
Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging .

HY-P1514

Peptide YY (PYY), human	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Endocrinology
Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.

HY-120619

BMS-193885 1 Publications Verification	Neuropeptide Y Receptor	Neurological Disease Endocrinology
BMS-193885 is a selective neuropeptide Y1 receptor antagonist (K_i=3.3 nM) that competitively blocks the receptor to inhibit NPY-mediated appetite regulation signaling pathways, reduce food intake and inhibit weight gain. BMS-193885 has good blood-brain barrier penetration and is mainly used in the study of obesity and related metabolic diseases .

HY-P10000

Peptide YY (PYY) (3-36), Human	Neuropeptide Y Receptor	Metabolic Disease
Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .

HY-N0614S

Sucralose-d6 E955-d₆; Trichlorosucrose-d₆	Endogenous Metabolite	Cancer
Sucralose-d₆ is deuterium labeled Sucralose. Sucralose?(E955; Trichlorosucrose) is a?non-nutritive?artificial?sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

HY-B1136

Menbutone 1 Publications Verification Genabilic acid	Drug Derivative	Metabolic Disease
Menbutone (Genabilic acid), an oxobutyric acid derivative, is a choleretic. Menbutone can be used to treat digestive upsets (loss of appetite, indigestion, toxemia, or hepatic and pancreatic insufficiencies) in a variety of animal species, including different farm animals (cattle, sheep, goats, pigs), as well as in dogs .

HY-Y0337S2

L-Cysteine-3-13C Cysteine-¹³C	Endogenous Metabolite	Metabolic Disease
L-Cysteine-3- ¹³C is the ¹³C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-Y0337S

L-Cysteine-13C3,15N 2 Publications Verification	Endogenous Metabolite	Metabolic Disease
L-Cysteine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-14423

Velneperit 1 Publications Verification S2367	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease
Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity .

HY-13676R

Megestrol acetate (Standard) 2 Publications Verification	Reference Standards Progesterone Receptor Autophagy HIV	Endocrinology Cancer
Megestrol acetate (Standard) is the analytical standard of Megestrol acetate. This product is intended for research and analytical applications. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-116649

CB1 antagonist 2 AM4113	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 2 (AM4113) is an orally active cannabinoid receptor type 1 (CB1R) antagonist. CB1 antagonist 2 suppresses appetite, reduces body weight, and blocks addictive behaviors such as heroin addiction, without causing adverse effects like nausea and depression that are associated with traditional CB1 inverse agonists. CB1 antagonist 2 can be used in studies related to obesity and opioid addiction .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-Y0337R

L-Cysteine (Standard) 1 Publications Verification Cysteine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Cancer
L-Cysteine (Standard) is the analytical standard of L-Cysteine. This product is intended for research and analytical applications. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-P1304

CART(55-102)(human)	Neuropeptide Y Receptor	Neurological Disease
CART(55-102)(human) is an endogenous satiety factor with potent appetite-suppressing activity. CART(55-102)(human) is closely associated with leptin and neuropeptide Y .

HY-Y0337S4

L-Cysteine-13C3 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
L-Cysteine- ¹³C₃ is the ¹³C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-P1305

CART(55-102)(rat)	Neuropeptide Y Receptor	Neurological Disease
CART(55-102)(rat) is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) can induces anxiety and stress-related behavior .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-B1716S

L-5-Hydroxytryptophan-d3 L-5-HTP-d₃; Oxitriptan-d₃	Endogenous Metabolite	Neurological Disease Metabolic Disease
L-5-Hydroxytryptophan-d₃ is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-135615A

Desmethyl Sibutramine hydrochloride N-Desmethylsibutramine hydrochloride	Serotonin Transporter	Neurological Disease Metabolic Disease
Desmethyl Sibutramine hydrochloride, the secondary metabolite of Sibutramine, is an orally active norepinephrine transporter (NET) and serotonin transporter (SERT) inhibitor. Desmethyl Sibutramine hydrochloride can be used in the research of obesity and appetite suppressant .

HY-122477

Zylofuramine	Drug Derivative	Neurological Disease
Zylofuramine is a psychomotor stimulant. Zylofuramine can be used in the research related to appetite suppressants and Alzheimer's disease .

HY-P1021A

Peptide YY (PYY) (3-36), porcine TFA 3 Publications Verification	Neuropeptide Y Receptor	Metabolic Disease
Peptide YY (PYY) (3-36), porcine TFA is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite .

HY-P1339B

Orexin B, human acetate 1 Publications Verification Human orexin B acetate	Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with K_i of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-N0614R

Sucralose (Standard) E955 (Standard); Trichlorosucrose (Standard)	Reference Standards Endogenous Metabolite	Cancer
Sucralose (Standard) is the analytical standard of Sucralose. This product is intended for research and analytical applications. Sucralose?(E955; Trichlorosucrose) is a?non-nutritive?artificial?sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

HY-W015616

Benzylacetone 4-Penylbutan-2-one	Environmental Pollutants Tyrosinase	Infection Metabolic Disease
Benzylacetone (4-Penylbutan-2-one) is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC₅₀ of 2.8 mM, a K_i of 1.25 mM for monophenolase and an IC₅₀ of 0.6 mM, a K_i of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .

HY-B1716R

L-5-Hydroxytryptophan (Standard) 3 Publications Verification L-5-HTP (Standard); Oxitriptan (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease Metabolic Disease
L-5-Hydroxytryptophan (Standard) is the analytical standard of L-5-Hydroxytryptophan. This product is intended for research and analytical applications. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-P10380

palm11-PrRP31	Neuropeptide FF Receptor	Neurological Disease Metabolic Disease
palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC₅₀=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .

HY-P1421

Obestatin(human)	PERK GHSR Apoptosis	Metabolic Disease
Obestatin(human) is a 23-amino acid amidated peptide that regulates appetite and gastrointestinal motility via its interaction with GPR39. Obestatin(human) can be used for weight loss. Obestatin(human) cannot penetrate the cell membrane .

HY-Y0337S1

L-Cysteine-15N 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
L-Cysteine- ¹⁵N is the ¹⁵N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-Y0337S3

L-Cysteine-1-13C	Endogenous Metabolite	Metabolic Disease
L-Cysteine-1- ¹³C is the ¹³C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-101480

Xylamidine	5-HT Receptor	Neurological Disease
Xylamidine is a peripheral 5-HT receptor antagonist used to investigate possible peripheral appetite suppressant effects of 5-hydroxytryptophan (5-HTP) and fenfluramine. In a 1-hour food intake test, xylamidine attenuated the decrease in food intake induced by 5-HT and 5-HTP, but had no effect on fenfluramine, suggesting that the appetite suppressant effect of 5-HTP is mediated in part through peripheral 5-HT receptors. Microstructural analysis revealed that 5-HTP and fenfluramine induced a decrease in food intake rate and a reduction in feeding batch size. Xylamidine reversed the effects of 5-HTP on food intake rate and induced a slight increase in feeding batch size itself, thus, the peripheral effect of 5-HTP appears to be to slow food intake rate. No effect of xylamidine on fenfluramine-induced changes in feeding was observed. The results suggest that the appetite suppressant effects of 5-HTP and fenfluramine are differentiated based on the peripheral effects of 5-HTP. The peripheral effects of 5-HTP are distinct from the previously reported 5-HT-induced decreases in feeding batch size and duration. Possible mechanisms underlying the differences in peripheral effects of 5-HT and 5-HTP are discussed.

HY-B1716S2

L-5-Hydroxytryptophan-d4 L-5-HTP-d₄; Oxitriptan-d₄	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
L-5-Hydroxytryptophan-d₄ (L-5-HTP-d₄; Oxitriptan-d₄) is a deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-P1021

Peptide YY (PYY) (3-36), porcine	Neuropeptide Y Receptor	Metabolic Disease
Peptide YY (PYY) (3-36), porcine is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library

3,558 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,558 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L121

5-HT Receptor Compound Library

405 compounds

5-HT receptors, also called Serotonin receptors, are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. These receptors are now classified into seven families, 5-HT1–7, comprising a total of 14 structurally and pharmacologically distinct mammalian 5-HT receptor subtypes. The 5-HT receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

MCE 5-HT Receptor Compound Library consists of 405 5-HT receptor inhibitors and activators, which can be used for neuropsychiatric disorders drugs discovery.

Cat. No.	Product Name	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Biochemical Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-124187

Pinolenic acid ethyl ester

Ethyl pinolenate

Biochemical Assay Reagents

Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

HY-N0614GL

Sucralose (GMP Like) E955 (GMP Like); Trichlorosucrose (GMP Like)	Biochemical Assay Reagents
Sucralose (GMP Like) (E955 (GMP Like)) is the GMP Like class Sucralose (HY-N0614) that can be used as pharmaceutical excipients. Sucralose (E955; Trichlorosucrose) is a non-nutritive artificial sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

Cat. No.	Product Name	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P10798

Eloralintide LY-3841136	Amylin Receptor	Metabolic Disease
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity .

HY-P10746

EB1002	Neurokinin Receptor	Metabolic Disease
EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P10798A

Eloralintide sodium LY-3841136 sodium	Amylin Receptor Calcium Channel	Metabolic Disease
Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca ²⁺ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity .

HY-P11274A

Zenagamtide sodium Amycretin sodium; NN 9487 sodium	Amylin Receptor Insulin Receptor GCGR	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-18678A

Bremelanotide Acetate 1 Publications Verification PT-141 Acetate	Melanocortin Receptor	Metabolic Disease
Bremelanotide (PT-141) Acetate is a melanocortin receptor agonist. Bremelanotide Acetate can activate MC4R and increases dopamine release. Bremelanotide Acetate induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide Acetate can be used for the research of hypoactive sexual desire disorders .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-18678

Bremelanotide 1 Publications Verification PT-141	Melanocortin Receptor	Neurological Disease Metabolic Disease
Bremelanotide (PT-141) is a melanocortin receptor agonist. Bremelanotide can activate MC4R and increases dopamine release. Bremelanotide induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide can be used for the research of hypoactive sexual desire disorders .

HY-106224B

Orexin A (human, rat, mouse) acetate 10+ Cited Publications Hypocretin-1 (human, rat, mouse) acetate	Orexin Receptor (OX Receptor)	Neurological Disease
Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging .

HY-P1514

Peptide YY (PYY), human	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Endocrinology
Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.

HY-P11274

Zenagamtide Amycretin; NN 9487	Amylin Receptor GCGR Insulin Receptor	Metabolic Disease
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .

HY-P10000

Peptide YY (PYY) (3-36), Human	Neuropeptide Y Receptor	Metabolic Disease
Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P1304

CART(55-102)(human)	Neuropeptide Y Receptor	Neurological Disease
CART(55-102)(human) is an endogenous satiety factor with potent appetite-suppressing activity. CART(55-102)(human) is closely associated with leptin and neuropeptide Y .

HY-P1305

CART(55-102)(rat)	Neuropeptide Y Receptor	Neurological Disease
CART(55-102)(rat) is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) can induces anxiety and stress-related behavior .

HY-P1021A

Peptide YY (PYY) (3-36), porcine TFA 3 Publications Verification	Neuropeptide Y Receptor	Metabolic Disease
Peptide YY (PYY) (3-36), porcine TFA is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite .

HY-P1339B

Orexin B, human acetate 1 Publications Verification Human orexin B acetate	Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with K_i of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-P10380

palm11-PrRP31	Neuropeptide FF Receptor	Neurological Disease Metabolic Disease
palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC₅₀=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .

HY-P1421

Obestatin(human)	PERK GHSR Apoptosis	Metabolic Disease
Obestatin(human) is a 23-amino acid amidated peptide that regulates appetite and gastrointestinal motility via its interaction with GPR39. Obestatin(human) can be used for weight loss. Obestatin(human) cannot penetrate the cell membrane .

HY-P1021

Peptide YY (PYY) (3-36), porcine	Neuropeptide Y Receptor	Metabolic Disease
Peptide YY (PYY) (3-36), porcine is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

HY-P3691

CART (1-39), Human	Neuropeptide Y Receptor	Neurological Disease
CART (1-39), Human, Rat is a neuropeptide consisting of 1-39 residues of the CART peptide. CART (1-39), Human, Rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (1-39), Human, Rat inhibits both normal and starvation-induced feeding. CART (1-39), Human, Rat can induce anxiety and stress-related behavior .

HY-P2703

Peptide YY (pig)	Neuropeptide Y Receptor	Metabolic Disease Endocrinology
Peptide YY (pig) is a 36 amino acid gastrointestinal peptide, can be isolated from porcine duodenum. Peptide YY (pig) decreases appetite and food-intake by activation of the Y2 receptor. Peptide YY (pig) is present mainly in pancreatic endocrine cells with effect on both intestinal motility and the cardiovascular system .

HY-P10380A

palm11-PrRP31 TFA	Neuropeptide FF Receptor	Neurological Disease Metabolic Disease
palm11-PrRP31 TFA is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 TFA is GPR10 (EC₅₀=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 TFA is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 TFA can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .

HY-P1304A

CART(55-102)(human) TFA	Neuropeptide Y Receptor	Neurological Disease
CART(55-102)(human) TFA is a human satiety factor with potent appetite-suppressing activity. CART(55-102)(human) TFA is closely associated with leptin and neuropeptide Y .

HY-P3692

CART (55-76), rat	Neuropeptide Y Receptor	Neurological Disease
CART (55-76), rat is a neuropeptide (55-76 residues of the CART peptide) and constitutes the N-terminal fragments of CART (55-102). CART (55-76), rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (55-76), rat can induce anxiety and stress-related behavior .

HY-P1339AS1

Orexin B, human-13C18,15N3 TFA Human orexin B-13C18,15N3 TFA	Isotope-Labeled Compounds Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human- ¹³C₁₈, ¹⁵N₃ (Human orexin B- ¹³C₁₈, ¹⁵N₃) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-P2592

Ro 23-7014	Cholecystokinin Receptor	Others
Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .

HY-P6176

JLB2-110c	Melanocortin Receptor	Metabolic Disease Endocrinology
JLB2-110c activates MCRs receptor (mMC4R EC₅₀ = 0.34 nM) and has a strong in vivo appetite suppressant effect .

HY-P10379

palm-PrRP31	Neuropeptide FF Receptor	Others Neurological Disease
palm-PrRP31 is a potent dual receptor agonist for both GPR10 (EC₅₀=72 pM) and NPFF-R2. palm-PrRP31 activates downstream signaling pathways through binding to its receptors, GPR10 and NPFF-R2, which results in reduced appetite and increased energy expenditure. Utilizing palm-PrRP31 facilitates the study of the mechanism of action in the nervous system, thereby elucidating the complex biological processes that regulate appetite and energy expenditure .

HY-P2025

JMV 236	Histone Methyltransferase	Neurological Disease
JMV 236 is a cholecystokinin antagonist with appetite-suppressing activity. JMV 236 affects the regulation of food intake through the interaction of the intestinal endogenous peptide PrRP and the CCK1 receptor. The administration of JMV 236 activates PrRP neurons located in the NTS, thereby enhancing its appetite-suppressing effect. JMV 236 has significant effects on areas of the central nervous system associated with food intake, especially during states of starvation .

HY-P1305A

CART(55-102)(rat) TFA	Neuropeptide Y Receptor	Neurological Disease
CART(55-102)(rat) TFA is a rat satiety factor with potent appetite-suppressing activity. CART(55-102)(rat) TFA is closely associated with leptin and neuropeptide Y. CART(55-102)(rat) TFA can induces anxiety and stress-related behavior .

HY-P10267

Neuromedin (B-30)	Bombesin Receptor	Neurological Disease Inflammation/Immunology
Neuromedin B-30 is the neuropeptide, which is orignally isolated from porcine brain and spinal cord. , and may exhibit activity in stimulating smooth-muscle. Neuromedin B causes local vasodilation, increases vascular permeability and local hyperalgesia, thereby participating in neurogenic inflammation. Neuromedin B regulates appetite, body temperature, and behavioral responses to stress. Neuromedin B is also involved in regulating smooth muscle contraction and secretory function in the gastrointestinal tract .

HY-P1339AS

Orexin B, human-13C6,15N TFA Human orexin B-13C6,15N TFA	Isotope-Labeled Compounds Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human- ¹³C₆, ¹⁵N (Human orexin B- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0337

L-Cysteine Maximum Cited Publications 12 Publications Verification Cysteine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite
L-Cysteine (Cysteine) is an orally active conditionally essential amino acid with hypoglycemic effects, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine promotes the proliferation and differentiation of neural stem cells via the CBS/H2S pathway. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. L-Cysteine can be used as an anorectic agent .

HY-Y0337A

L-Cysteine hydrochloride Maximum Cited Publications 12 Publications Verification	Structural Classification Classification of Application Fields Anti-aging Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) .

HY-W016715

L-Cysteine hydrochloride hydrate Maximum Cited Publications 12 Publications Verification	Classification of Application Fields Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB Insulin Receptor
L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes .

HY-B1716

L-5-Hydroxytryptophan 3 Publications Verification L-5-HTP; Oxitriptan	Monophenols other families Phenols Amino acids Plants Endogenous metabolite	Endogenous Metabolite
L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-Y0079

D-Phenylalanine	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
D-Phenylalanine is an atypical D-amino acid and an inhibitor of bacterial biofilm formation. D-Phenylalanine mainly replaces D-alanine (D-Ala) by incorporating into the fourth and fifth positions of bacterial peptidoglycan (PG), changing the cell wall structure, enhancing bacterial acid resistance and affecting biofilm formation. D-Phenylalanine may promote the secretion of peptide tyrosine tyrosine (PYY) in mammals by activating the intestinal GPR109B receptor. D-Phenylalanine can inhibit the maturation of microbial biofilms and promote the release of specific hormones. It can be used for antibacterial preservation, improving the yield of probiotics in the food industry, and studying appetite regulation and blood sugar control in metabolic diseases such as diabetes .

HY-Y0337R

L-Cysteine (Standard) 1 Publications Verification Cysteine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Amino acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
L-Cysteine (Standard) is the analytical standard of L-Cysteine. This product is intended for research and analytical applications. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-W015616

Benzylacetone 4-Penylbutan-2-one	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Thymelaeaceae Metabolic Disease Plants Aquilaria sinensis (Lour.) Spreng. Disease Research Fields Source Classification	Environmental Pollutants Tyrosinase
Benzylacetone (4-Penylbutan-2-one) is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC₅₀ of 2.8 mM, a K_i of 1.25 mM for monophenolase and an IC₅₀ of 0.6 mM, a K_i of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .

HY-B1716R

L-5-Hydroxytryptophan (Standard) 3 Publications Verification L-5-HTP (Standard); Oxitriptan (Standard)	Structural Classification Alkaloids Monophenols other families Ketones, Aldehydes, Acids Phenols Amino acids Plants Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
L-5-Hydroxytryptophan (Standard) is the analytical standard of L-5-Hydroxytryptophan. This product is intended for research and analytical applications. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-W153897

N-Methyltyramine	Alkaloids Human Gut Microbiota Metabolites Microorganisms Leguminosae Other Alkaloids Acacia auriculiformis A.Cunn. ex Benth Plants Endogenous metabolite Source Classification	Adrenergic Receptor
N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .

HY-W153897R

N-Methyltyramine (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Microorganisms Leguminosae Other Alkaloids Acacia auriculiformis A.Cunn. ex Benth Plants Endogenous metabolite Source Classification	Adrenergic Receptor Reference Standards
N-Methyltyramine (Standard) is the analytical standard of N-Methyltyramine. This product is intended for research and analytical applications. N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .

HY-Y0337AR

L-Cysteine hydrochloride (Standard)	Structural Classification Amino acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
L-Cysteine (hydrochloride) (Standard) is the analytical standard of L-Cysteine (hydrochloride). This product is intended for research and analytical applications. L-Cysteine hydrochloride is an orally active conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride suppresses ghrelin and reduces appetite in rodents. L-Cysteine hydrochloride inhibits Aspergillus flavus growth and AFB synthesis by disrupting cell structure and antioxidant system balance. L-Cysteine hydrochloride enhances relaxant responses of rat aortic rings to NO and reduces responses to endothelium-derived relaxing factor (EDRF) [4].

HY-W016715R

L-Cysteine hydrochloride hydrate (Standard)	Structural Classification Amino acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
L-Cysteine (hydrochloride hydrate) (Standard) is the analytical standard of L-Cysteine (hydrochloride hydrate). This product is intended for research and analytical applications. L-Cysteine hydrochloride hydrate is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate suppresses ghrelin and reduces appetite in rodents and humans .

HY-N19062

Caralluma fimbriata extract	Structural Classification Extract	Others
Caralluma fimbriata extract is often used to suppress appetite and aid in weight management.

HY-N18781

Chitrakmool extract	Structural Classification Extract	Bacterial
Chitrakmool extract contains a variety of key active ingredients, including the potent naphthoquinone compound pampinidin, as well as various alkaloids, flavonoids, and terpenoids. Chitrakmool extract helps stimulate appetite, improve digestion, and relieve indigestion, bloating, and constipation.

HY-W015616R

Benzylacetone (Standard) 4-Penylbutan-2-one (Standard)	Structural Classification Ketones, Aldehydes, Acids Thymelaeaceae Plants Aquilaria sinensis (Lour.) Spreng. Source Classification	Tyrosinase Reference Standards
Benzylacetone (4-Penylbutan-2-one) (Standard) is the analytical standard of Benzylacetone (HY-W015616). This product is intended for research and analytical applications. Benzylacetone is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC₅₀ of 2.8 mM, a K_i of 1.25 mM for monophenolase and an IC₅₀ of 0.6 mM, a K_i of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .

Cat. No.	Product Name	Chemical Structure

HY-Y0337S5

L-Cysteine-d3
L-Cysteine-d₃ is the deuterium labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-N0614S

Sucralose-d6
Sucralose-d₆ is deuterium labeled Sucralose. Sucralose?(E955; Trichlorosucrose) is a?non-nutritive?artificial?sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

HY-Y0337S2

L-Cysteine-3-13C
L-Cysteine-3- ¹³C is the ¹³C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-Y0337S

L-Cysteine-13C3,15N 2 Publications Verification
L-Cysteine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-Y0337S4

L-Cysteine-13C3 1 Publications Verification
L-Cysteine- ¹³C₃ is the ¹³C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-B1716S

L-5-Hydroxytryptophan-d3

L-5-Hydroxytryptophan-d₃ is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-Y0337S1

L-Cysteine-15N 1 Publications Verification
L-Cysteine- ¹⁵N is the ¹⁵N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-Y0337S3

L-Cysteine-1-13C
L-Cysteine-1- ¹³C is the ¹³C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-B1716S2

L-5-Hydroxytryptophan-d4

L-5-Hydroxytryptophan-d₄ (L-5-HTP-d₄; Oxitriptan-d₄) is a deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-Y0337S6

L-Cysteine-d2 1 Publications Verification
L-Cysteine-d₂ is the deuterium labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-13676S

Megestrol acetate-d3

Megestrol acetate-d₃ is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-P1339AS1

Orexin B, human-13C18,15N3 TFA
Orexin B, human- ¹³C₁₈, ¹⁵N₃ (Human orexin B- ¹³C₁₈, ¹⁵N₃) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-Y0337S7

L-Cysteine-d3,15N
L-Cysteine-d₃, ¹⁵N is the deuterium and ¹⁵N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans .

HY-13676S1

Megestrol acetate-d3-1

Megestrol acetate-d₃-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-B1716S1

L-5-Hydroxytryptophan-d3-1

L-5-Hydroxytryptophan-d₃-1 is the deuterium labeled L-5-Hydroxytryptophan . L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

HY-P1339AS

Orexin B, human-13C6,15N TFA
Orexin B, human- ¹³C₆, ¹⁵N (Human orexin B- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Orexin B, human (HY-P1339). Orexin B, human is the agonist for Orexin Receptor, with K_is of 420 nM and 36 nM for OX1 and OX2. Orexin B, human participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-B1716SA

L-5-Hydroxytryptophan-d3 hydrate

L-5-Hydroxytryptophan-d₃ (L-5-HTP-d₃) hydrate is the deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan-d₃ is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .

Host:	Rabbit (3)
Reactivity:	Human (3) Mouse (1)
Application:	IHC-P (3)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P810376

	Obestatin Antibody (YA9696) appetite regulating hormone, Ghrelin 27, Ghrelin 28, Ghrelin and obestatin prepropeptide, Ghrelin, Ghrelin/obestatin prepropeptide, ghrl, GHRL_HUMAN, Growth hormone releasing peptide, Growth hormone secretagogue	IHC-P	Human, Mouse
	Obestatin Antibody (YA9696) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to Obestatin.

HY-P81482

	Obestatin Antibody (YA1227) GHRL; MTLRP; UNQ524/PRO1066; appetite-regulating hormone; Growth hormone secretagogue; Growth hormone-releasing peptide; Motilin-related peptide; Protein M46; Ghrelin-27Ghrelin-28 (Ghrelin); Obestatin	IHC-P	Human
	Obestatin Antibody (YA1227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Obestatin.

HY-P81482A

	Obestatin Antibody (YA1227)(PBS only) GHRL; MTLRP; UNQ524/PRO1066; appetite-regulating hormone; Growth hormone secretagogue; Growth hormone-releasing peptide; Motilin-related peptide; Protein M46; Ghrelin-27Ghrelin-28 (Ghrelin); Obestatin	IHC-P	Human
	Obestatin Antibody (YA1227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Obestatin.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-N0614

Sucralose 3 Publications Verification E955; Trichlorosucrose		Sweetening Agents
Sucralose (E955; Trichlorosucrose) is a non-nutritive artificial sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0614GL

Sucralose (GMP Like) E955 (GMP Like); Trichlorosucrose (GMP Like)	Endogenous Metabolite	Cancer
Sucralose (GMP Like) (E955 (GMP Like)) is the GMP Like class Sucralose (HY-N0614) that can be used as pharmaceutical excipients. Sucralose (E955; Trichlorosucrose) is a non-nutritive artificial sweetener and sugar substitute. Sucralose can activate a conserved neural fasting response and thereby exerts an appetite-stimulating effect in rodents .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

appetite

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Natural
Products